TLX
NASDAQ
$10.51
Telix Pharmaceuticals Ltd (TLX)
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $21.04 (+100.19%)
Market Cap
$3.82B
Revenue 5Y CAGR
+127.76%
FCF 5Y CAGR
+43.67%
P/E Ratio
162.15
Price Chart
Valuation
Market Cap$3.82B
P/E162.15
Forward P/E2000.00
P/S4.76
P/B8.98
Profitability
Total Revenue (TTM)$1.33B
Gross Profit (TTM)$255M
EBITDA$107M
Profit Margin-1.2%
Operating Margin1.6%
EPS$0.07
Financial Health
Debt-to-Equity112.5%
Free Cash Flow Yield-0.89%
Growth & Risk
Revenue 5Y CAGR+127.76%
FCF 5Y CAGR+43.67%
Beta (5Y)0.90
Sharpe Ratio-0.51